Join IQVIA’s esteemed panel of experts for an in-depth discussion on how AI can meet and exceed these new expectations. This webinar delves into the intersection of regulatory frameworks and technological innovation, offering insights into the future of PV and how organizations can navigate this transformative field. Key takeaways include:

What if empowering sites to successfully navigate the challenges of today’s clinical trials was the first step in supporting a patient-centric approach to research? Download your free white paper to explore practical solutions for enabling patient-centric clinical trials by using innovative solutions and technologies for the benefit of sites, sponsors and patients alike. Read now to:

January 2025 sees the implementation of the Health Technology Assessment Regulation (HTAR) developed to reduce the admin burden and equalize access of important medicines to EU patients through a collaborative framework. New concepts such as JSC and JCA act as guidance for developers but are often complex and highly competitive. Discover more about the process, including:

The role of Medical Science Liaisons (MSLs) is rapidly evolving. According to field leaders, MSLs are increasingly interacting with new kinds of external stakeholders, driving insight generation and supporting strategic company goals through internal deployment of insights. To address this, IQVIA has developed a new MSL training approach to plug the skills gap and equip MSLs for success. Explore how IQVIA:

Since the 21st Century Cures Act in 2016 and subsequent FDA guidance, regulatory frameworks have evolved to incorporate RWD and RWE - allowing a broader set of data sources, including electronic health records (EHRs), claims, and registries, to be considered for regulatory decision making. In this white paper, explore key learnings about RWD/RWE in regulatory submissions, including:

The biologics market is growing rapidly, unlocking exciting opportunities but also presenting significant challenges. Developers are undergoing pressure to accelerate the delivery of innovative therapies while addressing complex regulatory demands, navigating demanding clinical trial phases, efficiently scaling production, and maintaining quality. In this webinar, industry experts will share practical strategies and real-world examples to help you navigate these challenges. Key takeaways:

To deliver these therapies to the patients who need them, their success hinges on effective storage and management to maintain integrity throughout their lifecycle. From early development to commercialization, safeguarding sensitive biological materials demands scalable storage solutions and meticulous risk mitigation strategies. Partnering with a CDMO specializing in ultracold storage and biorepository management is critical to preserving product integrity and ensuring continuity throughout every development stage. This webinar will explore how the right CDMO partner can streamline biological material storage, mitigate risks, and provide the scalability needed to support growth from clinical trials to commercial launch, empowering you to advance your pipeline with confidence. Participants will gain insight into:

Traditional payment methods negatively impact clinical trial participation, with over 50% failing to meet recruitment targets due to payment issues. To increase recruitment and retention, sponsors must adopt flexible, accessible, and user-friendly payment solutions. Gain expert insights on the payment landscape, including:

Financial burdens are cited as one of the main barriers to clinical trial recruitment and retention, with traditional methods proving unreliable, complicated and slow. For trial sites and sponsors, the administration burden can be overwhelming, especially on a global scale. Discover how IQVIA’s Participant Payment service is transforming the participant payment landscape, simplifying the process and driving clinical trial success, by offering: